

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 1 of 33

I. POLICY DESCRIPTION:

Antineoplastic Agent, Anti-CD20 monoclonal antibody – Rituxan (Rituximab), Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs)

II. RESPONSIBLE PARTIES:

Medical Management Administration, Pharmacy Department, Utilization Management, Integrated Care Management, Claims Department

III. DEFINITIONS:

Rituxan and its biosimilars are a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes which upon binding to CD20, mediates B-cell lysis.

IV. POLICY:

Rituximab and its biosimilars will be considered medically necessary once the following coverage criteria is met. Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Chart notes must be submitted to confirm diagnosis and previous treatment(s).

Ruxience is the preferred product. Rituxan, Riabni and Truxima require trial and failure with Ruxience.

Rituximab Approvable Indications	
1	Moderately to severely active Rheumatoid Arthritis (RA)
2	Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and microscopic polyangiitis (MPA) and Churg-Strauss and pauci-immune glomerulonephritis
3	Sjogren’s Syndrome
4	Multiple Sclerosis (MS)
5	Myasthenia Gravis
6	Immune or Idiopathic Thrombocytopenia (ITP)
7	Autoimmune blistering disease
8	Neuromyelitis optica (i.e., neuromyelitis optica spectrum disorder; NMOSD, Devic disease)
9	Systemic Lupus Erythematosus (SLE)
10	Thrombotic thrombocytopenic purpura
11	Oncology Indications
12	Pemphigus Vulgaris

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 2 of 33

INITIAL REQUEST:

1. Moderately to severely active Rheumatoid Arthritis (RA)

- A. Member is 18 years of age or older;
AND
- B. Prescribed by or in consultation with a Rheumatologist;
AND
- C. Member has a confirmed diagnosis of moderately to severely active rheumatoid arthritis (RA) as defined by ONE of the following:
 - a. ≥ 8 tender joints or painful on motion; and ≥ 6 swollen joints;
OR
 - b. High sensitivity C-reactive protein (hs-CRP) ≥ 7 mg/L or ESR ≥ 28 mm/H;
- AND**
- D. Member has tried, and indicated inadequate control, with ONE of the following agents (unless intolerant or contraindicated to):
 - a. Methotrexate in combination with another conventional Disease-modifying antirheumatic drugs (DMARD) for 3 months (see Appendix);
OR
 - b. Tumor necrosis factor (TNF) antagonist therapy (e.g., Humira, Enbrel, Simponi, Cimzia);
OR
 - c. Previously received at least two full doses of Rituxan, Ruxience, Truxima, or Riabni for the treatment of RA (most recent dose was given within 6 months of request);
- AND**
- E. Authorization is for no more than 12 months

2. Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and microscopic polyangiitis (MPA) and Churg-Strauss and pauci-immune glomerulonephritis

- A. Pediatric member is ≥ 2 years old;
AND
- B. Treatment of GPA, MPA, Churg-Strauss, or pauci-immune glomerulonephritis;
AND
- C. Authorization is for no more than 12 months

3. Sjogren’s Syndrome

- A. Member has tried, and indicated inadequate control, with ALL of the following agents (unless intolerant or contraindicated to):
 - a. Glucocorticoids;
AND

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 3 of 33

- b. Immunosuppressive agents (cyclophosphamide, azathioprine, mycophenolate or methotrexate);

AND

- B. Authorization is for no more than 12 months

4. Multiple Sclerosis (MS)

- A. Confirmed diagnosis of relapsing remitting multiple sclerosis;

AND

- B. Prescribed by or in consultation with a physician who specializes in the treatment of MS and/or a neurologist;

AND

- C. Medication will be administered 6 months after previous dose;

AND

- D. Rituximab will NOT be used in combination with any ONE of the following:

- a. Disease modifying therapy (e.g., interferon beta preparations, dimethyl fumarate, glatiramer acetate, natalizumab, fingolimod, cladribine, siponimod, or teriflunomide);

OR

- b. B-cell targeted therapy (e.g., ocrelizumab, belimumab, ofatumumab);

OR

- c. Lymphocyte trafficking blockers (e.g., alemtuzumab, mitoxantrone);

AND

- E. Authorization is for no more than 12 months

5. Myasthenia Gravis

- A. Member has tried, and indicated inadequate control, with ALL of the following agent(s) (unless intolerant or contraindicated to):

- a. Pyridostigmine;

AND

- b. Cyclophosphamide;

AND

- c. At least two immunosuppressive agents (azathioprine, mycophenolate cyclosporine, or methotrexate);

AND

- B. Authorization is for no more than 12 months

6. Immune or Idiopathic Thrombocytopenia (ITP)

- A. Medication is prescribed by or in consultation with a hematologist;

AND

- B. ONE of the following:

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 4 of 33

- a. Member has tried, and indicated inadequate control, with at least ONE of the following (unless intolerant or contraindicated to):
 - i. Intravenous immunoglobulin (IVIG);
OR
 - ii. Anti-D (RHO) immunoglobulin;
OR
 - iii. Corticosteroids;
OR
 - iv. Splenectomy;
- OR**
- b. Member has previously received course of a rituximab product for ITP and meets ALL of the following:
 - i. Medication will be administered 6 months after previous dose;
AND
 - ii. Documentation that member responded to therapy;
AND
 - iii. Prescriber confirmed member has relapsed disease;

AND

C. Authorization is for no more than 6 months (initial treatment is for a maximum of 4 doses);

7. Autoimmune blistering disease

- A. Prescribed by or in consultation with a dermatologist;
AND
- B. Therapy will be used in combination with a systemic corticosteroid;
AND
- C. Authorization is for no more than 12 months

8. Neuromyelitis optica (i.e., neuromyelitis optica spectrum disorder; NMOSD, Devic disease)

- A. Prescribed by or in consultation with a neurologist;
AND
- B. When at least one other immunotherapy was ineffective;
AND
- C. The member will not receive the requested drug concomitantly with other biologics for the treatment of NMOSD;
AND
- D. Authorization is for no longer than 12 months

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 5 of 33

9. Systemic Lupus Erythematosus (SLE)

- A.** Prescribed by or in consultation with a rheumatologist, nephrologist, or neurologist;
AND
- B.** Prior to initiating therapy, the member is positive for autoantibodies relevant to SLE (e.g., ANA, anti-ds DNA, anti-Sm);
AND
- C.** ONE of the following:
 - a.** Member is receiving a stable standard treatment for SLE with ONE of the following (alone or in combination):
 - i.** Glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone);
OR
 - ii.** Antimalarials (e.g., hydroxychloroquine);
OR
 - iii.** Immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide);
OR
 - b.** Member has previously received course of a rituximab product for SLE and meets ALL of the following:
 - i.** Medication will be administered 6 months after previous dose;
AND
 - ii.** Documentation that member responded to therapy;
AND
 - iii.** Prescriber confirmed member has relapsed disease;
AND
- D.** Authorization is for no more than 12 months

10. Thrombotic thrombocytopenic purpura

- A.** Prescribed by or in consultation with hematologist;
AND
- B.** Member has a positive ADAMTS13 protease antibody titer;
AND
- C.** Member meets ONE of the following:
 - a.** Member has had a suboptimal response to therapeutic plasma exchange;
OR
 - b.** Member has failed corticosteroid therapy;
AND
- D.** Authorization is for no more than 6 months

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 6 of 33

11. Oncology Indications:

A. ONE of the following:

- a.** Non-Hodgkin’s lymphoma (NHL) in adult patients with ONE of the following:
 - i.** Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent;
OR
 - ii.** Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy;
OR
 - iii.** Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent after first-line CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy;
OR
 - iv.** Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens;
OR
- b.** Chronic lymphocytic leukemia (CLL)
 - i.** Treatment is used in combination with fludarabine and cyclophosphamide (FC) in adult patients with previously untreated and previously treated CD20-positive CLL
- c.** AIDS-related B-cell lymphomas;
OR
- d.** Burkitt lymphoma;
OR
- e.** Castleman’s disease;
OR
- f.** Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL);
OR
- g.** Diffuse large B-cell lymphoma (DLBCL);
OR
- h.** Follicular lymphoma (FL);
OR
- i.** Hairy cell leukemia (Rituxan/Ruxience/Truxima only);
OR

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 7 of 33

- j.** Low- or high-grade B-cell lymphoma;
OR
- k.** MALT lymphoma (gastric or nongastric);
OR
- l.** Mantle cell lymphoma;
OR
- m.** Marginal zone lymphoma (nodal or splenic);
OR
- n.** Post-transplant lymphoproliferative disorder;
OR
- o.** Primary cutaneous B-cell lymphoma;
OR
- p.** Pediatric Aggressive Mature B-Cell Lymphomas;
OR
- q.** Central nervous system (CNS) cancers including ONE of the following:
 - i.** Leptomeningeal metastases from lymphomas;
OR
 - ii.** Primary CNS lymphomas;
- r.** Hodgkin’s lymphoma, nodular lymphocyte-predominant;

AND

B. Authorization is for no more than 12 months

12. Pemphigus Vulgaris (PV)

A. Member is 18 years of age or older;

AND

B. Member has moderate to severe disease as assessed utilizing an objective measure (i.e. Pemphigus Disease Area Index (PDAI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), Pemphigus Area and Activity Score (PAAS));

AND

C. Member has confirmed diagnosis of Pemphigus Vulgaris (PV) as determined by ONE of the following:

- a.** Clinical features (i.e., appearance of lesions, erosions and/or blisters, Nikolsky sign (induction of blistering via mechanical pressure at the edge of a blister or on normal skin), Characteristic scarring and lesion distribution);

OR

- b.** Histopathologic confirmation by skin/mucous membrane biopsy;

OR

- c.** Positive direct immunofluorescence (DIF) microscopy result;

OR

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 8 of 33

- d. Presence of autoantibodies as detected by direct immunofluorescence or enzyme-linked immunosorbent assay (ELISA);

AND

- D. Member has tried and failed the following agents in individually and in combination after at least 3 months unless intolerant or contraindicated:

- a. Corticosteroids;

AND

- b. DMARD (cyclophosphamide, azathioprine, methotrexate, mycophenolate);

AND

- E. Authorization is for no more than 12 months;

RENEWAL REQUEST:

1. Rheumatoid Arthritis

- A. Initial conditions of coverage have been met for continued treatment in all members (including new members);

AND

- B. Member has achieved or maintained a positive clinical response after at least two doses of therapy with Rituxan, Ruxience, Truxima, or Riabni as evidenced by disease activity improvement of at least 20% from baseline in ONE of the following:

- a. Tender joint count;

OR

- b. Swollen joint count;

OR

- c. Pain;

OR

- d. Disability;

AND

- C. Medication will be administered 6 months after previous dose;

AND

- D. Authorization is for no more than 12 months

2. Multiple Sclerosis

- A. Initial conditions of coverage have been met;

AND

- B. Member has relapsing remitting multiple sclerosis (MS);

AND

- C. Member has experienced disease stability or improvement while receiving Rituxan, Ruxience, Truxima, or Riabni;

AND

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 9 of 33

D. Authorization is for no more than 12 months

3. Oncology Indications

- A. Initial conditions of coverage have been met;
AND
- B. Member has an oncologic indication;
AND
- C. Member has no evidence of disease progression or unacceptable toxicity;
AND
- D. Authorization is for no more than 12 months

4. All other indications

- A. Initial conditions of coverage have been met for continued treatment in all members (including new members);
AND
- B. Member has received benefit from therapy;
AND
- C. Authorization is for no more than 12 months

V. APPENDIX:

Examples of contraindications to methotrexate:

1. Clinical diagnosis of alcohol use disorder, alcoholic liver disease or other chronic liver disease
2. Breastfeeding
3. Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia)
4. Elevated liver transaminases
5. History of intolerance or adverse event
6. Hypersensitivity
7. Interstitial pneumonitis or clinically significant pulmonary fibrosis
8. Myelodysplasia
9. Pregnancy or currently planning pregnancy
10. Renal impairment
11. Significant drug interaction

VI. LIMITATIONS/ EXCLUSIONS:

The use of Rituxan and its biosimilars is considered to be experimental and investigational if prescribed for indications that have not been approved by the FDA and will not be covered under this policy.

Coverage will not be provided for requests for the treatment of rheumatoid arthritis (RA) when planned date of administration is less than 16 weeks since date of last dose received.

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 10 of 33

Member will not receive Rituxan, Ruxience, Truxima, or Riabni with other biologics for RA.

Member will not receive Rituxan, Ruxience, Truxima, or Riabni with other multiple sclerosis (MS) drugs excluding Ampyra.

VII. APPLICABLE PROCEDURE CODES:

CPT	Description
J9312	Injection, rituximab, 10 mg (Rituxan)
Q5115	Injection, rituximab-abbs, biosimilar, 10 mg (Truxima)
Q5119	Injection, rituximab-pvvr, biosimilar, 10 mg (Ruxience)
Q5123	Injection, rituximab-arrx, biosimilar, 10 mg (Riabni)

VIII. APPLICABLE DIAGNOSIS CODES:

CODE	Description
C82.00	Follicular lymphoma grade I, unspecified site
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes
C82.07	Follicular lymphoma grade I, spleen
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites
C82.10	Follicular lymphoma grade II, unspecified site
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes
C82.17	Follicular lymphoma grade II, spleen
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 11 of 33

C82.20	Follicular lymphoma grade III, unspecified, unspecified site
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes
C82.27	Follicular lymphoma grade III, unspecified, spleen
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
C82.30	Follicular lymphoma grade IIIa, unspecified site
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
C82.37	Follicular lymphoma grade IIIa, spleen
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites
C82.40	Follicular lymphoma grade IIIb, unspecified site
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C82.47	Follicular lymphoma grade IIIb, spleen
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 12 of 33

C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites
C82.50	Diffuse follicle center lymphoma, unspecified site
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes
C82.57	Diffuse follicle center lymphoma, spleen
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites
C82.60	Cutaneous follicle center lymphoma, unspecified site
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes
C82.67	Cutaneous follicle center lymphoma, spleen
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites
C82.80	Other types of follicular lymphoma, unspecified site
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes
C82.87	Other types of follicular lymphoma, spleen
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 13 of 33

C82.89	Other types of follicular lymphoma, extranodal and solid organ sites
C82.90	Follicular lymphoma, unspecified, unspecified site
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes
C82.97	Follicular lymphoma, unspecified, spleen
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites
C83.00	Small cell B-cell lymphoma, unspecified site
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes
C83.07	Small cell B-cell lymphoma, spleen
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites
C83.30	Diffuse large B-cell lymphoma, unspecified site
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes
C83.37	Diffuse large B-cell lymphoma, spleen
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 14 of 33

C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes
C83.57	Lymphoblastic (diffuse) lymphoma, spleen
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites
C83.70	Burkitt lymphoma, unspecified site
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck
C83.72	Burkitt lymphoma, intrathoracic lymph nodes
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb
C83.76	Burkitt lymphoma, intrapelvic lymph nodes
C83.77	Burkitt lymphoma, spleen
C83.78	Burkitt lymphoma, lymph nodes of multiple sites
C83.79	Burkitt lymphoma, extranodal and solid organ sites
C83.80	Other non-follicular lymphoma, unspecified site
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
C83.87	Other non-follicular lymphoma, spleen
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 15 of 33

C83.91	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck
C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes
C83.94	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb
C83.95	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites
C83.99	Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites
C85.10	Unspecified B-cell lymphoma, unspecified site
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck
C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes
C85.17	Unspecified B-cell lymphoma, spleen
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 16 of 33

C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes
C85.87	Other specified types of non-Hodgkin lymphoma, spleen
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C85.97	Non-Hodgkin lymphoma, unspecified, spleen
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse
C91.A0	Mature B-cell leukemia Burkitt-type not having achieved remission
C91.A1	Mature B-cell leukemia Burkitt-type, in remission

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 17 of 33

C91.A2	Mature B-cell leukemia Burkitt-type, in relapse
L10.0	Pemphigus vulgaris
M05.00	Felty's syndrome, unspecified site
M05.011	Felty's syndrome, right shoulder
M05.012	Felty's syndrome, left shoulder
M05.019	Felty's syndrome, unspecified shoulder
M05.021	Felty's syndrome, right elbow
M05.022	Felty's syndrome, left elbow
M05.029	Felty's syndrome, unspecified elbow
M05.031	Felty's syndrome, right wrist
M05.032	Felty's syndrome, left wrist
M05.039	Felty's syndrome, unspecified wrist
M05.041	Felty's syndrome, right hand
M05.042	Felty's syndrome, left hand
M05.049	Felty's syndrome, unspecified hand
M05.051	Felty's syndrome, right hip
M05.052	Felty's syndrome, left hip
M05.059	Felty's syndrome, unspecified hip
M05.061	Felty's syndrome, right knee
M05.062	Felty's syndrome, left knee
M05.069	Felty's syndrome, unspecified knee
M05.071	Felty's syndrome, right ankle and foot
M05.072	Felty's syndrome, left ankle and foot
M05.079	Felty's syndrome, unspecified ankle and foot
M05.09	Felty's syndrome, multiple sites
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 18 of 33

M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 19 of 33

M05.69	Felty's syndrome, unspecified knee
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 20 of 33

M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 21 of 33

M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site
M06.80	Other specified rheumatoid arthritis, unspecified site
M06.811	Other specified rheumatoid arthritis, right shoulder
M06.812	Other specified rheumatoid arthritis, left shoulder

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 22 of 33

M06.819	Other specified rheumatoid arthritis, unspecified shoulder
M06.821	Other specified rheumatoid arthritis, right elbow
M06.822	Other specified rheumatoid arthritis, left elbow
M06.829	Other specified rheumatoid arthritis, unspecified elbow
M06.831	Other specified rheumatoid arthritis, right wrist
M06.832	Other specified rheumatoid arthritis, left wrist
M06.839	Other specified rheumatoid arthritis, unspecified wrist
M06.841	Other specified rheumatoid arthritis, right hand
M06.842	Other specified rheumatoid arthritis, left hand
M06.849	Other specified rheumatoid arthritis, unspecified hand
M06.851	Other specified rheumatoid arthritis, right hip
M06.852	Other specified rheumatoid arthritis, left hip
M06.859	Other specified rheumatoid arthritis, unspecified hip
M06.861	Other specified rheumatoid arthritis, right knee
M06.862	Other specified rheumatoid arthritis, left knee
M06.869	Other specified rheumatoid arthritis, unspecified knee
M06.871	Other specified rheumatoid arthritis, right ankle and foot
M06.872	Other specified rheumatoid arthritis, left ankle and foot
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot
M06.88	Other specified rheumatoid arthritis, vertebrae
M06.89	Other specified rheumatoid arthritis, multiple sites
M06.8A	Other specified rheumatoid arthritis, other specified site
M06.9	Rheumatoid arthritis, unspecified
M31.30	Wegener's granulomatosis without renal involvement
M31.31	Wegener's granulomatosis with renal involvement
M31.7	Microscopic polyangiitis

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 23 of 33

IX. REFERENCES:

1. Rituxan [package insert]. South San Francisco, CA: Genentech, Inc.; December 2021.
2. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. *Blood*. 2013 Mar 14;121(11):1976-81. doi: 10.1182/blood-2012-09-455691. Epub 2013 Jan 4.
3. Heelan K, Al-Mohammed F, Smith MJ, et al. Durable Remission of Pemphigus With a Fixed-Dose Rituximab Protocol. *JAMA Dermatol*. 2014 Feb 5. doi: 10.1001/jamadermatol.2013.6739. [Epub ahead of print]
4. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. *Br J Haematol* 2004;125:232-239.
5. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. *Blood*. 2008;112(4):999-1004.
6. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. *Blood* 2001;98:952-957.
7. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. *Semin Oncol* 2000;27(suppl 12):99-103.
8. Delgado J, Bustos JG, Jimenez-Yuste V, Hernandez-Navarro F. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. *Haematologica* 2002;87:215-216.
9. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. *Haematologica* 2002;87:189-195.
10. Giagounidis AAN, Anhof J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the antiCD20 monoclonal antibody rituximab: a pilot study. *Eur J Haematol* 2002;69:95-100.
11. Garcia-Chavez J, Majluf-Cruz, Montiel-Cervantes L, et al. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. *Ann Hematol*. 2007;86(12):871-7.
12. Mueller BU, Bennett CM, Feldman HA, et al. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. *Pediatr Blood Cancer*. 2009 Feb;52(2):259-62.
13. Wang W, Yu Qh, Zhang HY et al. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura]. *Zhonghua Nei Ke Za Zhi*. 2008 Mar;47(3):225-7.

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 24 of 33

14. Provan D, Butler T, Evangelista ML, et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. *Haematologica*. 2007 Dec;92(12):1695-8.
15. Narang M, Penner JA, Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). *Am J Hematol*. 2003 Dec;74(4):263-7.
16. Meo P, Stipa E, La Presa M, et al. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study]. *Recenti Prog Med*. 2002 Jul-Aug;93(7-8):421-7.
17. Joly P, Mouquet H, Roujea JC. A Single cycle of Rituximab for the Treatment of Severe Pemphigus. *N Eng J Med*. 2007. 357(6):545-52.
18. Ahmed AR, Spigelman Z, Cavacini LA. Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin. *N Eng J Med*. 2006. 355(17):1772-9.
19. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. *J Am Acad Dermatol* 2002;47:785-788.
20. Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). *Arch Dermatol* 2004;140:91-96.
21. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. *Int J Dermatol*. 2008 Mar;47(3):292-4.
22. Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. *J Dermatolog Treat*. 2007;18(5):312-4.
23. Esposito, M, Capriotti E, Giunta A, et al. Long-lasting remission of pemphigus vulgaris treated with rituximab. *Acta DermatoVenereologica*. 2006. 86(1):87-9.
24. Wenzel J, Bauer R, Bieber T, Tuting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. *Acta Dermato-Venereologica*. 2005. 85(2):185-6.
25. Schmidt E, Herzog S, Brocker EB, et al. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. *British Journal of Dermatology*. 2005. 153(2):449-51.
26. Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. *J Dtsch Dermatol Ges*. 2008 May;6(5):366-73. doi: 10.1111/j.1610-0387.2007.06602.x. Epub 2008 Jan 14.
27. Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2011 Jan;17(1):1-17.

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 25 of 33

28. Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. *Eur J Haematol.* 2013 Dec;91(6):546-51. doi: 10.1111/ejh.12199. Epub 2013 Oct 3.
29. Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. *Br J Haematol.* 2013 Nov;163(3):393-9.
30. Maung SW, Leahy M, O'Leary HM, et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. *Br J Haematol.* 2013 Oct;163(1):118-22.
31. Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. *Ann Hematol.* 2010 Nov;89(11):1073-80.
32. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). *J Neurol.* 2014 Jan;261(1):1-16. doi: 10.1007/s00415-013-7169-7. Epub 2013 Nov 23.
33. D'Arena G, Califano C, Annunziata M, et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. *Eur J Haematol* 2007 July;79(1):53-8.
34. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. *Lancet* 2001;358:1511-1513. Rituximab (Raibni™, Rituxan®, Ruxience® , & Truxima®
35. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. *Leukemia* 2002;16:2092-2095.
36. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. *Blood.* 2003;101(10):3857-61.
37. Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. *Pediatr Blood Cancer.* 2007;50(4):822-5.
38. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evan syndrome. *Mayo Clin Proc.* 2003;78(11):1340-6.
39. Heidel F, Lipka DB, von Auer C, et al. Addition of rituximab to standard therapy improves response rate and progressionfree survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anemia. *Throm Haemost* 2007 February;97(2):228-33.

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 26 of 33

40. Perrotta S, Locatelli F, La Manna A, et al. Anti-CD20 monoclonal antibody (rituximab) for life-threatening auto-immune haemolytic anaemia in a patient with systemic lupus erythematosus. *Br J Haematol* 2002;116:465-467.
41. Svahn J, Fioredda F, Calvillo M, et al. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants. *British Journal of Dermatology*. 2009;145(1):96-100.
42. Motto DG, Williams JA, & Boxer LA: Rituximab for refractory childhood autoimmune hemolytic anemia. *Isr Med Assoc J* 2002; 4(N11):1006-1008.
43. Narat S, Gandla J, & Mehta AB: Anti-CD20 monoclonal antibody in the treatment of refractory autoimmune cytopenias in adults. *Blood* 2004;104:742A.
44. Narat S, Gandla J, Hoffbrand AV, et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. *Haematologica*. 2005;90(9):1273-4.
45. Noel N, Monnet X, Angel N, Goujard C, Lambotte O. Life threatening steroid-resistant autoimmune anemia successfully treated with rituximab: a case report. *Am J Hematol*. 2009;84(3):193.
46. Garay G, Riveros D, Milone J, et al: Refractory autoimmune cytopenias, either associated with lymphoproliferative diseases or idiopathic in adult patients, treated with anti-CD20 monoclonal antibody (Rituximab). *Blood* 2004; 104(11, Part 2):238B.
47. D'Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. *Am J Hematol*. 2006;81(8):598-602.
48. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. *Blood* 2004;103:2925-2928.
49. Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. *Leuk Lymphoma*. 2006 Feb;47(2):253–260.
50. Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. *Haematologica*. 2010 Nov;95(11):1935-42.
51. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum*. 2012 Apr;64(4):1215-26.
52. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum* 2010; 62(1):222-233.
53. Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. *JAMA Neurol*. 2013 Sep 1;70(9):1177-1179.

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 27 of 33

54. Tanaka Y, Kazuhiko Y, Takeuchi T, et al. A multi-center phase I/II trial of rituximab for refractory systemic lupus erythematosus. *Mod Rheumatol* 2007;17:191-197.
55. Leandro MJ, Cambridge G, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. *Rheumatology (Oxford)*. 2005; 44(12):1542-5. Rituximab (Raibni™, Rituxan®, Ruxience® , & Truxima®)
56. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. *Arthritis Rheum*. 2005;52(10):3168-74.
57. Anolik JH, Barnard J, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. *Arthritis Rheum*. 2004;50(11):3580-90.
58. Jonsdottier T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. *Ann Rheum Dis*. 2008 Mar;67(3):330-4.
59. Gunnarsson I, Sundalin B, Jonsdottier T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. *Arthritis Rheum*. 2007;56(4):263-72.
60. Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. *Arthritis Rheum*. 2006;54(9):2970-82.
61. Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. *J Pediatr*. 2006;148(5):623-7.
62. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. *Arthritis Rheum*. 2004;50(8):2580-9.
63. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. *Arthritis Res Ther*. 2006;8(3): R83.
64. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. *Arthritis Rheum*. 2006 Nov;54(11):3612-22.
65. Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. *Ann Rheum Dis*. 2008;67(7):1011-6.
66. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. *Ann Rheum Dis*. 2008;67(12):1724-31.
67. Tamimoto Y, Horiuchi T, Tsukamoto H, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. *Rheumatology (Oxford)*. 2008;47(6):821-7.
68. Ruxience [package insert] New York, NY: Pfizer, Inc.; October 2023.

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 28 of 33

69. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N Eng J Med*. 2008 Feb 14;358(7):676-88.
70. Barr-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. *Ann Neurol*. 2008 Mar;63(3):395-400.
71. Monson NL, Cravens PD, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. *Arch. Neurol*. 2005;62(2):258-64.
72. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. *Neurology* 1999;52:1701-1704.
73. Kilidireas C, Anagnostopoulos A, Karandreas N, et al. Rituximab therapy in monoclonal IgM-related neuropathies. *Leuk Lymphoma*. 2006 May;47(5):859-64.
74. Neunert C, Terrell D, Arnold D, et al. The American Society of Hematology 2019 evidence-based practice guideline for immune thrombocytopenia. *Blood*. 2019 Dec 10;3(23):3829-3866.
75. MCG™ Care Guidelines, 22nd edition, 2018, Rituximab ACG:A-0448 (AC).
76. von Bonin M, Oelschlägel U, Radke J, Stewart M, Ehninger G, Bornhauser M, Platzbecker U. Treatment of chronic steroidrefractory graft-versus-host disease with low-dose rituximab. *Transplantation*. 2008 Sep 27;86(6):875-9.
77. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy. *JAMA Neurol*. 2014 Jan 20.
78. National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium® (NCCN Compendium®). Available at https://www.nccn.org/professionals/drug_compendium/content/. Accessed February 6, 2019.
79. Sato D, Callegaro D, Lana-Peixoto MA, Fujihara K. Treatment of neuromyelitis optica: an evidence based review. *Arq Neuropsiquiatr* 2012;70(1);59-66.
80. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpes virus-related multicentric Castlemans disease with anti-CD20 monoclonal antibody therapy. *Blood* 2001;98:3473-3475.
81. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. *Blood* 2002;99:1092-1094.
82. Dunganwalla M, Marsh JC, Tooze JA, et al. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. *Ann Hematol*. 2007 Mar;86(3):191-7. Epub 2006 Nov 23.
83. Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. *Blood* 2002;100:3426-3428.
84. Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. *Haematologica*. 2007 Jan;92(1):66-71.

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 29 of 33

85. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. *Muscle Nerve* 2003;27:611-615.
86. Remuzzi G, Chiurciu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy. *Lancet* 2002;360:923-924.
87. Ruggenti P, Chiurciu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: A one-year prospective study. *J Am Soc Nephrol* 2003;14:1851-1857.

88. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. *Kidney Int.* 2008 Jan;73(1):117-25.
89. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, Ferrara JL, Uberti JP. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. *Biol Blood Marrow Transplant.* 2003 Aug;9(8):505-11.
90. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. *Bone Marrow Transplant.* 2007 Aug;40(3):273-7.
91. Teshima T, Najafuji K, Henzan H, et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. *Int J Hematol* 2009;90:253–260.
92. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. *Blood* 2006;108:756-62.
93. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. *Transplantation* 2004;77:542-548.
94. Kim S, Kim W, Li XF, et al. Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years. *Arch Neurol.* 2011;68(11):1412-1420.
95. Scott TF, Frohman EM, DeSeze J, et al. Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2011 Dec 13;77(24):2128-34.
96. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. *Arch Dermatol.* 2007 Jun;143(6):763-7.
97. Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. *Arthritis Rheum.* 2007 Sep;56(9):3107-11.
98. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. *J Rheumatol.* 2007 Sep;34(9):1864-8.
99. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. *Arthritis Rheum.* 2005 Feb;52(2):601-7.

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 30 of 33

100. He D, Guo R, Zhang F, et al. Rituximab for relapsing-remitting multiple sclerosis. *Cochrane Database Syst Rev.* 2013 Dec 6;12:CD009130.
101. Léger JM, Viala K, Nicolas G, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. *Neurology.* 2013 Jun 11;80(24):2217-25.
102. Zara G, Zambello R, Ermani M. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy. *Clin Neurophysiol.* 2011 Dec;122(12):2518-22.
103. FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab):<http://www.fda.gov/Drugs/DrugSafety/ucm366406.htm>. Accessed February 4, 2014.
104. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. *Ann Neurol.* 2009 Mar;65(3):286-93. doi: 10.1002/ana.21577.
105. Berezne GL, Galicier, A. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. *J Clin Oncol* 2007; 25:3350–3356.
106. van Dorp S, Resemann H, te Boome L, Pietersma F, van Baarle D, Gmelig-Meyling F, de Weger R, Petersen E, Minnema M, Lokhorst H, Ebeling S, Beijm SJ, Knol EF, van Dijk M, Meijer E, Kuball J. The immunological phenotype of rituximabsensitive chronic graft-versus-host disease: a phase II study. *Haematologica.* 2011 Sep;96(9):1380-4.
107. Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2015, Issue 1. Art. No.: CD007356.
108. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Management of ImmunotherapyRelated Toxicities, Version 1.2019. Accessed February 5, 2019.
109. Truxima [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; February 2022.
110. Dane K, Chaturvedi S. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. *Hematology.* 2018 Nov 30;2018(1):539-547.
111. Froissart A, Buffet M, Veyradier A, et al; Experience of the French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. *Crit Care Med.* 2012;40(1):104-111.
112. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. *Blood.* 2011;118(7):1746-1753.

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 31 of 33

113. Ineichen BV, Moridi T, Granbert T, et al. Ritiximab treatment for multiple sclerosis. *Mult Scler*. 2019 Jun 25:1352458519858604.
114. Granqvist M, Boremalm M, Poorghobad A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. *JAMA Neuro* 2018; 75(3):320-327.
115. Castillo-Trivino T, Braithwaite D, Bacchetti P, et al. Ritixiumab in relapsing and progressive forms of multiple sclerosis: a systematic review. *PloS One*. 2013 Jul 2;8(7):366308.
116. Riabni [package insert]. Thousand Oaks, CA: Amgen, Inc.; February 2023.
117. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. *J Am Acad Dermatol*. 2008 June; 58(6): 1043–1046. doi: 10.1016/j.jaad.2008.01.012. Avail at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829665/pdf/nihms82304.pdf>



Policy and Procedure

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 32 of 33

REVISION LOG:

REVISIONS	INITIAL	DATE
Creation date	SC	4/28/2023
Update	AKC	11/28/2023
Update	AKC	12/29/2023
Annual Review	AKC	12/17/2024

Approved: 12/27/2024 <i>Suzana Patel</i> Suzana Patel, PharmD Senior Director of Pharmacy	Date:	Approved: <i>SSS</i> Sanjiv Shah, MD Chief Medical Officer	Date: 04.03.26
--	--------------	--	--------------------------



Policy and Procedure

Title: UM-PT019 Rituximab	Division: Medical Management Department: Pharmacy
Approval Date: 4/28/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 4/28/2023	Policy Number: UM-PT019
Review Date: 12/17/2024	Cross Reference Number:
Retired Date:	Page 33 of 33

Medical Guideline Disclaimer:

Property of MetroPlus HealthPlan. All rights reserved. The treating physician or primary care provider must submit MetroPlus Health Plan clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, Metroplus Health Plan will not be able to properly review the request for prior authorization. The clinical review criteria expressed in this policy reflects how MetroPlus Health Plan determines whether certain services or supplies are medically necessary. MetroPlus Health Plan established the clinical review criteria based upon a review of currently available clinical information(including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). MetroPlus Health Plan expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by MetroPlus Health Plan, as some programs exclude coverage for services or supplies that MetroPlus Health Plan considers medically necessary. If there is a discrepancy between this guidelines and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and website links are accurate at time of publication.

MetroPlus HealthPlan has adopted the herein policy in providing management, administrative and other services to our members, related to health benefit plans offered by our organization.